Severe Liver Injury Associated with Zafirlukast
Authors: Silvio Danese, Italo De Vitis, Antonio Gasbarrini
Journal: Annals of Internal Medicine (2001)

Letters20 November 2001Severe Liver Injury Associated with ZafirlukastSilvio Danese, MD, Italo De Vitis, MD, and Antonio Gasbarrini, MDSilvio Danese, MDCatholic University of Rome; 00168 Rome, Italy (Danese, De Vitis, Gasbarrini)Search for more papers by this author, Italo De Vitis, MDCatholic University of Rome; 00168 Rome, Italy (Danese, De Vitis, Gasbarrini)Search for more papers by this author, and Antonio Gasbarrini, MDCatholic University of Rome; 00168 Rome, Italy (Danese, De Vitis, Gasbarrini)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-10-200111200-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read with interest the paper by Reinus and coworkers on three cases of severe liver injury after administration of the leukotriene receptor antagonist zafirlukast (1). We report a similar case of a 55-year-old woman who developed severe hepatitis after zafirlukast administration. She was admitted to the hospital with nausea, vomiting, fatigue, and mild abdominal pain in the right upper quadrant. She was taking zafirlukast, 20 mg twice per day for 5 months, and albuterol sulfate nasal spray.Levels of aspartate aminotransferase (10.92 µkat/L [655 U/L]) and alanine aminotransferase (20 217 nkat/L [1213 U/L]) were elevated. (Normal ...Reference1. Reinus JF, Persky S, Burkiewicz JS, Quan D, Bass NM, Davern TJ. Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast. Ann Intern Med. 2000;133:964-8. [PMID: 11119397] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Catholic University of Rome; 00168 Rome, Italy (Danese, De Vitis, Gasbarrini) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSevere Liver Injury after Treatment with the Leukotriene Receptor Antagonist Zafirlukast John F. Reinus , Seth Persky , Jill S. Burkiewicz , David Quan , Nathan M. Bass , and Timothy J. Davern Montelukast-Induced Hepatitis Marc F. Goldstein , James Anoia , and Martin Black Metrics Cited ByDrugs and ToxinsZafirlukastNonsteroidal Antiinflammatory Drugs and Leukotriene Receptor AntagonistsHepatic injury due to drugs, herbal compounds, chemicals and toxinsImportant Elements for the Diagnosis of Drug-Induced Liver InjuryProbable montelukast-induced hepatotoxicity in a pediatric patient: case reportCysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trendsThe Effects of Zafirlukast on Capsular Contracture: Preliminary ReportZafirlukastDrugs acting on the respiratory tractMontelukast-Induced HepatitisMarc F. Goldstein, MD, James Anoia, MD, and Martin Black, MDAcute hepatitis associated with montelukastLeukotriene antagonistsA Case of Montelukast-Induced HepatotoxicityDrugs acting on the respiratory tractDrug-induced liver diseaseZafirlukast 20 November 2001Volume 135, Issue 10Page: 930KeywordsLiverLiver diseasesNauseaNecrosisResearch laboratoriesSerum glutamic oxaloacetic transaminaseSulfatesToxicityUltrasound imagingVomiting ePublished: 20 November 2001 Issue Published: 20 November 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...